As of my last update in January 2022, I don't have access to specific real-time datasets, including a specific "US cancer analysis dataset." However, there are several well-known sources where you might find such datasets:

1. Surveillance, Epidemiology, and End Results (SEER) Program: SEER is a comprehensive source of cancer statistics in the United States, operated by the National Cancer Institute (NCI). They provide a wide range of cancer-related data including incidence, mortality, survival, and population-based data on cancer cases.

2. National Program of Cancer Registries (NPCR): This program, also managed by the Centers for Disease Control and Prevention (CDC), collects cancer incidence data at the state level.

3. CDC WONDER: The CDC's Wide-ranging Online Data for Epidemiologic Research (WONDER) platform provides access to a wide array of public health-related datasets, including cancer statistics.

4. National Cancer Database (NCDB): This database, jointly sponsored by the American College of Surgeons and the American Cancer Society, contains hospital registry data from over 1,500 Commission on Cancer (CoC)-accredited facilities.

5. National Health Interview Survey (NHIS): While not specific to cancer, the NHIS collects data on health and health-related behaviors, which may include information on cancer screenings, risk factors, and prevalence.

6. Behavioral Risk Factor Surveillance System (BRFSS): Similar to NHIS, BRFSS collects state-based, cross-sectional data about U.S. residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services, which may include cancer-related data.

7. National Health and Nutrition Examination Survey (NHANES): NHANES collects data on the health and nutritional status of a nationally representative sample of the U.S. population through interviews, physical examinations, and laboratory tests, which may include cancer-related information.

When accessing these datasets, it's essential to review their documentation thoroughly to understand the variables available, the methodology of data collection, any limitations or biases, and the terms of use. Additionally, many of these datasets require approval or registration before access is granted.

Explore historical ownership and registration records by performing a reverse Whois lookup for the email address any-read.net-owner-ncdb@customers.whoisprivacycorp.com..

BackgroundThe treatment for locally advanced breast cancer (LABC) is a severe clinical problem. The postoperative radiotherapy is a conventional treatment method for patients with LABC, whereas the effect of preoperative radiotherapy on outcome of LABC remains controversial. This study aimed to examine and compare the overall survival (OS) in patients with LABC who underwent preoperative radiotherapy or postoperative radiotherapy.MethodsThis retrospective cohort study included 41,618 patients with LABC from the National Cancer Database (NCDB) between 2010 and 2014. We collected patients’ demographic, clinicopathologic, treatment and survival information. Propensity score was used to match patients underwent pre-operative radiotherapy with those who underwent post-operative radiotherapy. Cox proportional hazard regression model was performed to access the association between variables and OS. Log-rank test was conducted to evaluate the difference in OS between groups.ResultsThe estimated median follow-up of all included participants was 69.6 months (IQR: 42.84-60.22); 70.1 months (IQR: 46.85-79.97) for postoperative radiotherapy, 68.5 (IQR: 41.13-78.23) for preoperative radiotherapy, and 67.5 (IQR: 25.92-70.99) for no radiotherapy. The 5-year survival rate was 80.01% (79.56-80.47) for LABC patients who received postoperative radiotherapy, 64.08% (57.55-71.34) for preoperative radiotherapy, and 59.67% (58.60-60.77) for no radiotherapy. Compared with no radiation, patients receiving postoperative radiotherapy had a 38% lower risk of mortality (HR=0.62, 95%CI: 0.60-0.65, p